"description","label","id","instanceType","uuid:ID","name","text"
"Main objective","","Objective_1","Objective","e0e50385-6416-4c0a-8fe4-40ea8f0eceb0","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"Safety","","Objective_2","Objective","c607e4e7-61e7-4840-a0a0-c4127ba2ce12","OBJ2","To document the safety profile of the xanomeline TTS."
"Behaviour","","Objective_3","Objective","6d79bc33-49f5-4ce6-b9dc-b6cce7b16ff9","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"","","Objective_4","Objective","d04916c5-a60c-49bc-8c19-700b804a82e4","OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"","","Objective_5","Objective","d71ed8dd-8edd-4679-b3b8-312ed9784e7c","OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"","","Objective_6","Objective","22bc547f-31b4-454b-a131-c253bb8c57a9","OBJ6","To assess the treatment response as a function of Apo E genotype."
